A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-09-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerfunctionreceptorpriorheart
  Phrases that lowered it: days beforeovariancombinationoralwithin 14
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.3% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 114 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Sponsor's past trials: 527 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 6.1% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 64.6% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 20411 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer NCT04719273 · started 2021 · scored riskier than 98% of active trials completed
• Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) NCT04738292 · started 2021 · scored riskier than 97% of active trials terminated
• Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer NCT02120469 · started 2014 · scored riskier than 58% of active trials completed
• TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer NCT02586675 · started 2016 · scored riskier than 69% of active trials completed
• Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer NCT02684227 · started 2016 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.